The Scale Was Never the Problem
- 1 day ago
- 2 min read
By Suzy Chase
Suzy Chase has stepped on a scale every morning for nearly three years. For the first of those years, the number set the tone for her entire day. Then came a realization that reshaped how she understood her own body: the scale wasn't measuring fat. It was measuring water, inflammation, glycogen, last night's dinner, yesterday's training, her sleep, her stress — all at once, with none of the context.
"The scale isn't lying," Chase says. "It's telling you a story without context. And without context, a number means nothing."
That insight became the foundation of The GLP-1 AI Method, which the longtime podcaster launched after a one year 50-pound transformation on a GLP-1.
With more than 20 years in podcasting behind her, Chase had built a career on helping people make sense of things. Health optimization became her next subject — and the gap was glaring: most people on these medications have no framework for understanding what's actually happening in their bodies. So she built one.
The method is deceptively simple. Each morning, Chase opens an AI assistant — ChatGPT, Claude, or Gemini — enters her weight, adds the context that matters (training, stress, sleep, recent patterns), and asks one question: "Is this number worth reacting to?" What comes back is clarity. Water retention. Recovery from a hard session. Within normal range. A number, finally, with a story attached.
"GLP-1 isn't the strategy," she says. "It's a variable inside a method."
That distinction drives everything. GLP-1 companies sell the drug; Chase sells the understanding — the difference between reacting and deciding. When people can't read what they're seeing, she argues, they overcorrect: eating too little, training too hard, choosing out of fear. When they understand, they hold steady. And holding steady, especially through the maintenance phase, is where lasting progress actually lives.
That shift is what her earliest customers describe. "I finally understand what my body is actually doing" is the line she hears most. The GLP-1 AI Method already has paying customers and early revenue validation, with a near-term goal of 50 customers and a six-month target north of 500 active users. The opportunity is large and underserved — millions of Americans are now on GLP-1 medications, growing roughly 40% year over year — and Chase believes the fitness-focused segment, people who want to use their data rather than just take the drug, has been almost entirely ignored.
She's growing an audience around the idea through Dinner Party on a GLP-1, a companion podcast where she unpacks the method and explores health and fitness for people on these medications. Her thesis fits in a sentence: the scale was never the problem. Not understanding was.
Connect With Suzy
Comments